NEW ORLEANS, LA—A PCSK9 inhibitor used on top of lipid-lowering therapy, including a high-intensity statin, significantly cuts the risk of major adverse cardiovascular events compared with placebo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results